ID: ALA4588355

Max Phase: Preclinical

Molecular Formula: C22H17N3

Molecular Weight: 323.40

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  C#CCNc1ccc2nc(C)c(-c3ccc4ccccc4c3)nc2c1

Standard InChI:  InChI=1S/C22H17N3/c1-3-12-23-19-10-11-20-21(14-19)25-22(15(2)24-20)18-9-8-16-6-4-5-7-17(16)13-18/h1,4-11,13-14,23H,12H2,2H3

Standard InChI Key:  MTICCVZWXPWAJF-UHFFFAOYSA-N

Associated Targets(non-human)

Astrocyte 64 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 323.40Molecular Weight (Monoisotopic): 323.1422AlogP: 4.80#Rotatable Bonds: 3
Polar Surface Area: 37.81Molecular Species: NEUTRALHBA: 3HBD: 1
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 3.02CX LogP: 4.15CX LogD: 4.15
Aromatic Rings: 4Heavy Atoms: 25QED Weighted: 0.55Np Likeness Score: -1.17

References

1. Le Douaron G, Ferrié L, Sepulveda-Diaz JE, Amar M, Harfouche A, Séon-Méniel B, Raisman-Vozari R, Michel PP, Figadère B..  (2016)  New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models.,  59  (13): [PMID:27341519] [10.1021/acs.jmedchem.6b00297]

Source